

Cytokine and CAM Antagonists: Miscellaneous Utilization Management Criteria

| | |
|------------------------------|---|
| Therapeutic Class: | Cytokine and CAM Antagonists: Miscellaneous |
| Non-Preferred Agents: | Entyvio (vedolizumab), Orencia (abatacept) vial, Otezla XR (apremilast), Sotyktu (deucravacitinib), Spevigo (spesolimab-sbzo), Uplizna (inebilizumab-cdon), Velsipity (etrasimod) |
| Preferred Agents: | Orencia (abatacept) Clickject/syringe, Otezla (apremilast) |
| Implementation Date: | 1/1/2026 |
| Prepared For: | CT |
| PDL Status: | Non-preferred |
| Purpose: | The targeted immune modulators included in these criteria are a heterogenous group of medications designed and approved to target specific disease states. Through a variety of mechanisms of action these drugs work to regulate the immune response and by addressing autoimmune and chronic inflammatory diseases. Approved uses for these agents include rheumatoid arthritis (abatacept), polyarticular juvenile idiopathic arthritis (abatacept), psoriatic arthritis (abatacept, apremilast, and deucravacitinib), plaque psoriasis (apremilast and deucravacitinib), generalized pustular psoriasis (spesolimab), Crohn's disease (vedolizumab), ulcerative colitis (vedolizumab and etrasimod), oral ulcers associated with Behçet's Disease (apremilast), prophylaxis of acute graft-versus-host disease (abatacept), neuromyelitis optica spectrum disorder (inebilizumab), generalized myasthenia gravis (inebilizumab), and immunoglobulin G4-related disease (inebilizumab) . |

| Generic Name | Brand Name | Approved Indications | Route of Administration | Biosimilar/Generic Availability |
|-----------------|--|---|-------------------------|---------------------------------|
| Abatacept | Orencia [®] , Orencia [®] Clickject [™] | RA, pJIA, PsA, prophylaxis of GVHD | IV, SC | No |
| Apremilast | Otezla [®] | PsA, PsO, oral ulcers of Behçet's Disease | PO | No |
| Deucravacitinib | Sotyktu [™] | PsA, PsO | PO | No |
| Etrasimod | Velsipity [™] | UC | PO | No |
| Inebilizumab | Uplizna [®] | NMOSD, IgG4-RD, gMG | IV | No |
| Spesolimab-sbzo | Spevigo [®] | GPP | IV, SC | No |
| Vedolizumab | Entyvio [®] | CD, UC | IV, SC | No |

Abbreviations: CD, Crohn disease; gMG, generalized myasthenia gravis; GPP, generalized pustular psoriasis; GVHD, graft versus host disease; IV, intravenous; NMOSD, neuromyelitis optica spectrum disorder; pJIA, polyarticular juvenile idiopathic arthritis; PO, orally; PSA, psoriatic arthritis; PsO, plaque psoriasis; RA, rheumatoid arthritis; SC, subcutaneous; UC, ulcerative colitis



All authorizations must be prescribed in accordance with FDA approved labeling. Use of samples to initiate therapy does not meet step therapy and/or continuation of therapy prior authorization requirements. Prior therapies will be verified through pharmacy claims and/or submitted chart notes.

General Approval Criteria:

- Claim is for preferred agent **OR**
- Requested quantity in accordance with FDA approved product labelling
- For specific formulation requests
 - **For brand requests when a therapeutically equivalent generic is preferred:** Provider must provide a documented medical reason the preferred generic formulation cannot be used
 - **For generic requests when a therapeutically equivalent brand is preferred:** Provider must provide a documented medical reason the preferred brand formulation cannot be used
 - **For non-preferred dosage or formulation requests:** Provider must provide a documented medical reason the preferred dosage or formulation cannot be used

Initial Therapy – All the following must be met:

- **For Entyvio**
 - Prescribed by or in consultation with a gastroenterologist
 - Diagnosis of moderately to severely active ulcerative colitis **OR** moderately to severely active Crohn's disease
 - Trial of a preferred tumor necrosis factor inhibitor (TNFi)(30 days) or preferred ustekinumab biosimilar **OR** documented adverse event/adverse reaction or contraindication
 - Patient age is 18 years and older
- **For Orencia vials**
 - Prescribed by or in consultation with a specialist familiar with the treated disease state
 - Not used in combination with other potent immunosuppressants (i.e. biologic disease-modifying antirheumatic drugs or Janus kinase inhibitors)
 - Patient has been screened for tuberculosis (TB)
 - For use in the prophylaxis of graft-versus-host disease
 - Patient age is 2 years and older
 - Must use in combination with a calcineurin inhibitor and methotrexate
 - Documentation patient is undergoing hematopoietic stem cell transplantation
 - For all other approved indications: must provide medical reason patient cannot use Orencia Clickject or syringe **OR** documented trial and failure of preferred Orencia product
- **For Otezla XR**
 - Prescribed by or in consultation with a specialist familiar with the treated disease state
 - Diagnosis of:
 - Adult patients – One of the following
 - Active psoriatic arthritis
 - Plaque psoriasis in patients who are candidates for phototherapy or systemic therapy
 - Oral ulcers associated with Behçet's disease
 - Pediatric patients 6 years of age and older and weighing 50 kg or more– One of the following
 - Active psoriatic arthritis
 - Moderate to severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy

- Trial of a preferred Otezla formulation (30 days)
- Documented medical reason preferred Otezla formulation cannot be used
- **For Sotyktu**
 - Prescribed by or in consultation with a dermatologist or rheumatologist
 - Diagnosis of one of the following
 - Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
 - Active psoriatic arthritis in adults
 - Not used in combination with other potent immunosuppressants
 - Patient has been screened for tuberculosis (TB)
 - Liver function tests confirm patient does NOT have severe hepatic impairment (Child-Pugh C), *claim will deny if present as Sotyktu is not recommended in patients with severe hepatic impairment*
 - Trial and failure of a preferred Cytokine and CAM Antagonist agent FDA approved for the treated disease state (30 days) **OR** documented adverse event/adverse reaction or contraindication
 - Patient age is 18 years and older
- **For Spevigo**
 - Prescribed by or in consultation with a dermatologist or other specialist familiar with the treated disease state
 - Diagnosis of generalized pustular psoriasis (GPP)
 - Patient has been screened for tuberculosis (TB)
 - Patient age is 12 years and older
 - Patient weighs at least 40 kg
 - Intravenous formulation is limited to treatment of acute flares
 - Approval limited to 1 month for flares
 - Subcutaneous formulation is limited to use in the prevention of flares
- **For Uplizna**
 - Prescribed by or in consultation with a specialist familiar with the treated disease state
 - Diagnosis of one of the following:
 - Neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive
 - Immunoglobulin G4-related disease (IgG4-RD) and patient has experienced a prior disease flare requiring treatment with corticosteroids **OR** has had an adverse reaction/adverse event or contraindication to corticosteroids
 - Generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive
 - Patient does not have active hepatitis B, active or untreated latent tuberculosis, or other active infections
 - Patient age is 18 years and older
- **For Velsipity**
 - Prescribed by or in consultation with a gastroenterologist
 - Diagnosis of moderately to severely active ulcerative colitis
 - Patient has not experienced myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III or IV heart failure in the last 6 months
 - Patient does not have a history or presence of Mobitz type II second-degree or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker.

- Trial of a preferred tumor necrosis factor inhibitor (TNFi)(30 days) or preferred ustekinumab biosimilar **OR** documented adverse event/adverse reaction or contraindication
- The following assessments have been completed prior to initiation
 - Complete blood count
 - Cardiac evaluation
 - Liver function tests
 - Ophthalmic assessment
- Patient age is 18 years and older

Initial PA length: 1 year (1 month for Spevigo IV dosing indicated for flares)

Exclusion Criteria: Approval criteria not met

Continuation Therapy: Documented compliance on current therapy regimen **AND** Documented continued clinical benefit **AND**

- For specific formulation requests
 - **For brand requests when a therapeutically equivalent generic is preferred:** Provider must provide a documented medical reason the preferred generic formulation cannot be used
 - **For generic requests when a therapeutically equivalent brand is preferred:** Provider must provide a documented medical reason the preferred brand formulation cannot be used
 - **For non-preferred dosage or formulation requests:** Provider must provide a documented medical reason the preferred dosage or formulation cannot be used

Continuation Length: 1 year

References:

1. Drugs@FDA: FDA Approved Drug Products. Accessed August 2025. <https://www.accessdata.fda.gov/scripts/cder/daf/>
2. DailyMed: National Library of Medicine. Accessed August 2025. <https://dailymed.nlm.nih.gov/dailymed/index.cfm>
3. Facts and Comparisons eAnswers online. Waltham, MA: UpToDate Inc.; 2025. Accessed August 2025. Available <https://www.wolterskluwer.com/en/solutions/uptodate/enterprise/lexidrug-facts-and-comparisons>
4. Drugs@FDA: FDA approved drug products. Accessed August 2025. <https://www.accessdata.fda.gov/scripts/cder/daf/>.
5. US Food and Drug Administration. Purple Book: Database of Licensed Biological Products. US Food and Drug Administration. Updated April 27, 2023. Accessed August 2025. <https://purplebooksearch.fda.gov/>
6. Zafiriou E, Karampinis E, Giannoulis G, Gravani A, Gampeta S, Zachou K. Effective Management of Life-Threatening Generalized Pustular Psoriasis Flare With Spesolimab. *Cureus*. 2024;16(7):e64474. Published 2024 Jul 13. doi:10.7759/cureus.64474
7. Khosroshahi A, Wallace ZS, Crowe JL, et al. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. *Arthritis Rheumatol*. 2015;67(7):1688-1699. doi:10.1002/art.39132
8. Kümpfel T, Gighuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. *J Neurol*. 2024;271(1):141-176. doi:10.1007/s00415-023-11910-z
9. Orenzia. Package insert. Bristol-Myers Squibb, L.L.C.; 2024.
10. Otezla. Package insert. Amgen Inc.; 2025.
11. Sotyktu. Package insert. Bristol-Myers Squibb, L.L.C.; 2026.
12. Velsipity. Package insert. Pfizer Inc.; 2025.

13. Uplizna. Package insert. Amgen Inc.; 2025.
14. Spevigo. Package insert. Boehringer Ingelheim Pharmaceuticals, Inc.; 2025.
15. Entyvio. Package insert. Takeda Pharmaceuticals U.S.A., Inc.; 2024.
16. Perugino C, Culver EL, Khosroshahi A, et al. Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial. *Rheumatol Ther*. 2023;10(6):1795-1808. doi:10.1007/s40744-023-00593-7
17. Stone JH, Khosroshahi A, Zhang W, et al. Inebilizumab for Treatment of IgG4-Related Disease. *N Engl J Med*. 2025;392(12):1168-1177. doi:10.1056/NEJMoa2409712
18. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057
19. Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. *J Am Acad Dermatol*. 2020;82(6):1445-1486. doi:10.1016/j.jaad.2020.02.044
20. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. *J Am Acad Dermatol*. 2023;88(1):29-39. doi:10.1016/j.jaad.2022.07.002
21. Gordon H, Minozzi S, Kopylov U, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. *J Crohns Colitis*. 2024;18(10):1531-1555. doi:10.1093/ecco-jcc/jjae091
22. Feuerstein JD, Ho EY, Shmidt E, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. *Gastroenterology*. 2021;160(7):2496-2508. doi:10.1053/j.gastro.2021.04.022
23. Lichtenstein GR, Loftus EV, Afzali A, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol*. 2025;120(6):1225-1264. Published 2025 Jun 3. doi:10.14309/ajg.0000000000003465
24. Singh S, Loftus EV Jr, Limketkai BN, et al. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. *Gastroenterology*. 2024;167(7):1307-1343. doi:10.1053/j.gastro.2024.10.001
25. Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. *Am J Gastroenterol*. 2025;120(6):1187-1224. Published 2025 Jun 3. doi:10.14309/ajg.0000000000003463

Revision History

| Date | Version | Revisions |
|-----------|---------|--|
| 11/7/2025 | V1 | Document approved by DSS |
| 3/19/2026 | V2 | Edits made to coverage criteria for Sotyktu for and Uplizna. |